why are moderna shares surging?
Shares of Moderna rocketed by 156% to around $161 as of Wednesday morning, adding more than $100 in value to the stock after the firm announced results from its first-ever late-stage trial of an experimental melanoma vaccine. The vaccine, an mRNA-based shot combined with Merck’s immunotherapy drug Keytruda, marked the first successful final-stage study for any mRNA-based cancer therapy after Moderna said the drug helped cut the recurrence of severe skin cancer and extended the time patients lived without their melanoma returning.
Read more Harvard Will Pay $53 Million To Settle Lawsuits Over Body Parts Stolen From Morgue
further reading
ForbesModerna Shares Skyrocket 90% Toward Best Day Ever—On Success Of Cancer Drug TrialBy Ty Roush